Praxis Precision Medicines, Inc. (PRAX) stock is soaring in trading today, up 35% at time of writing, with shares reaching a value of $260, their highest value since the beginning of 2022. Current ...
Praxis Precision Medicines has reported a 56.3% median reduction in seizure frequency from baseline in a midphase trial, encouraging the biotech to push ahead with phase 2/3 plans despite almost a ...
Seven months ago, independent clinical trial observers peeked at interim data for Praxis Precision Medicines’ essential tremor drug and recommended stopping the Phase 3 studies. Praxis kept going. On ...
The last time I spoke about Praxis Precision Medicines, Inc. (PRAX), it was in a Seeking Alpha article entitled "Praxis: Still A 'Hold' Despite Interim Analysis Setback Of Ulixacaltamide." At that ...
BOSTON, May 11, 2023 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results